Search Results - Liyan Miao

What are the benefits of therapeutic drug monitoring in the optimization of adalimumab therapy? a systematic review and meta-analysis up to 2022 by Yun Li, Cheng Xie, Xiaoliang Ding, Ziyang Wu, Jingjing Zhang, Jianguo Zhu, Liyan Miao, Liyan Miao, Liyan Miao, Liyan Miao

Connect to this object online.

Association between genetic variants and development of antibodies to infliximab: A cross-sectional study in Chinese patients with Crohn's disease by Kouzhu Zhu, Kouzhu Zhu, Xiaoliang Ding, Xiaoliang Ding, Zhiyao Chen, Qinhua Xi, Xueqin Pang, Weichang Chen, Liyan Miao, Liyan Miao, Liyan Miao, Liyan Miao

Connect to this object online.

Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients by Xiaoliang Ding, Ruifang Zhu, Jian Wu, Ling Xue, Meihua Gu, Liyan Miao

Connect to this object online.

The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study by Xiaohuan Du, Xiaohuan Du, Chenrong Huang, Chenrong Huang, Ling Xue, Ling Xue, Zheng Jiao, Min Zhu, Jie Li, Jun Lu, Peifang Xiao, Xuemei Zhou, Chenmei Mao, Zengyan Zhu, Ji Dong, Xiaoxue Liu, Zhiyao Chen, Shichao Zhang, Yiduo Ding, Shaoyan Hu, Liyan Miao, Liyan Miao, Liyan Miao

Connect to this object online.

Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn's disease by Kouzhu Zhu, Kouzhu Zhu, Xiaoliang Ding, Xiaoliang Ding, Ling Xue, Ling Xue, Linsheng Liu, Linsheng Liu, Yan Wang, Yun Li, Qinhua Xi, Xueqin Pang, Weichang Chen, Liyan Miao, Liyan Miao

Connect to this object online.

A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans by Hua Zhang, Hua Zhang, Shu Yan, Yan Zhan, Sheng Ma, Sheng Ma, Yicong Bian, Yicong Bian, Shaorong Li, Junjun Tian, Guangze Li, Dafang Zhong, Xingxing Diao, Liyan Miao, Liyan Miao

Connect to this object online.

Dexmedetomidine Ameliorate CLP-Induced Rat Intestinal Injury via Inhibition of Inflammation by Yanqing Chen, Liyan Miao, Yusheng Yao, Weilan Wu, Xiaodan Wu, Cansheng Gong, Liangcheng Qiu, Jianping Chen

Connect to this object online.

Prevalence and influence factor of drug-related problems in inpatients with kidney disease: a prospective single central study by Guoguang Gu, Yanping Li, Yunyun Hu, Hengyi Zhao, Xingdong Wang, Xiaomin Li, Xinran Zhang, Hong Zhu, Xiaohua Dai, Xingxing Liu, Liyan Miao, Jianguo Zhu, Yongfu Hang

Connect to this object online.

Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody by Yan Wang, Donghui Pan, Chenrong Huang, Bingliang Chen, Mingzhu Li, Shuaixiang Zhou, Lizhen Wang, Min Wu, Xinyu Wang, Yicong Bian, Junjie Yan, Junjian Liu, Min Yang, Liyan Miao

Connect to this object online.

Pharmacokinetics, Mass Balance, and Biotransformation of [14C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects by Shumao Ni, Sheng Ma, Yingying Yu, Zhenwen Yu, Yujia Zhu, Xiaofen Sun, Lin Li, Caixia Sun, Hui Wang, Peng Peng, Zheming Gu, Hua Zhang, Frank Wu, Liyan Miao, Jean Fan

Connect to this object online.